Amylyx Pharmaceuticals Inc To Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program Transcript
Good afternoon, and thank you all for joining us today to discuss the treatment landscape for people living with Progressive Supranuclear Palsy or PSP, and our clinical development plans for AMX0035 and PSP. With me on the call today are Josh Cohen and Justin Klee, our Co-CEOs. Dr. Jamie Timmons, Head of Global Medical Strategy and Communications. Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital in Munich, Germany and who will be our primary investigator on the Global Phase III clinical trial of AMX0035 and PSP. And Dr. Lahar Mehta, our Head of Global Clinical Development. Joining us for Q&A will be Jim Frates, our Chief Financial Officer. (Operator Instructions)
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |